间充质干细胞治疗克罗恩病的研究进展

doi:10.20047/j.issn1673-7210.2023.13.12

摘要
图/表
参考文献(36)
相关文章 (15)

全文: PDF (476 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要克罗恩病（CD）是一种易复发且发病症状多样的慢性炎症性肠病，目前尚无特效治疗手段。间充质干细胞（MSCs）具有抗感染、免疫调节、组织修复等潜能，近年来国内外有较多应用MSCs治疗CD的临床研究。本文综述了利用骨髓MSCs和脂肪MSCs等治疗CD的相关报道，并从MSCs对自然杀伤细胞、树突状细胞、巨噬细胞、中性粒细胞和调节性T细胞的免疫调节机制及MSCs的组织修复能力方面，阐述了MSCs治疗CD的机制、效果和安全性，以期为未来CD的临床治疗提供新的思路和方法。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	吴小佳1 陈锦阳1 庄盼1 刘军权2▲

关键词 ：克罗恩病, 间充质干细胞, 治疗, 治疗机制

Abstract：Crohn’s disease (CD) is a chronic inflammatory bowel disease that is prone to relapse and has various symptoms. Currently, there is no effective treatment. Mesenchymal stem cells (MSCs) have the potential of anti-inflammatory, immune regulation, tissue repair, etc. In recent years, there have been many clinical studies on the application of MSCs in the treatment of CD at home and abroad. This article reviews the related reports on the use of bone marrow-derived MSCs and adipose-derived MSCs in the treatment of CD. In terms of the immune regulation mechanism of natural killer cells, dendritic cells, macrophages, neutrophils, and regulatory T cells and the tissue repair ability of MSCs, the mechanism, efficacy and safety of MSCs in the treatment of CD are described, in order to provide new ideas and methods for the clinical treatment of CD in the future.

Key words： Crohn’s disease Mesenchymal stem cells Therapy Therapeutic mechanism

基金资助:国家自然科学基金资助项目（82072512）。

通讯作者: ▲通讯作者

引用本文:

吴小佳1 陈锦阳1 庄盼1 刘军权2▲. 间充质干细胞治疗克罗恩病的研究进展[J]. 中国医药导报, 2023, 20(13): 54-57.
WU Xiaojia1 CHEN Jinyang1 ZHUANG Pan1 LIU Junquan2▲. Research advances in the treatment of Crohn’s disease with mesenchymal stem cells. 中国医药导报, 2023, 20(13): 54-57.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2023.13.12 或 https://www.yiyaodaobao.com.cn/CN/Y2023/V20/I13/54

[1] Sevana K，Eva R，Nassim H，et al. Mitochondrial impairment drives intestinal stem cell transition into dysfunctional Paneth cells predicting Crohn’s disease recurrence [J]. BMJ，2020，69（11）：1939-1951.
[2] Vassiliki S，Morris G，Anthony KA，et al. Interventions for the management of abdominal pain in Crohn’s disease and inflammatory bowel disease [J]. Cochrane Database Syst Rev，2021，11（11）：1-11.
[3] Ronald K，Nazar M，Laura F，et al. Quality of life in inflammatory bowel diseases：it is not all about the bowel [J]. Intest Res，2021，19（1）：45-52.
[4] Caruso R，Mathes T，Martens EC，et al. A specific gene-microbe interaction drives the development of Crohn’s disease-like colitis in mice [J]. Sci Immunol，2019，4（eaaw 4341）：1-14.
[5] Bamias G，Cominelli F. Exploring the Early Phase of Crohn’s Disease [J]. Clin Gastroenterol Hepato，2021，19（12）：2469- 2480.
[6] Iris S，Valentina KV，Barbara R，et al. Environmental Microbial Factors Determine the Pattern of Inflammatory Lesions in a Murine Model of Crohn’s Disease-Like Inflammation [J]. Inflamm Bowel Dis，2020，26（1）：66-79.
[7] Esther C，Reiner W，Michael S，et al. Dysbiotic microbiota interactions in Crohn’s disease [J]. Gut Microbes，2021，13（1）：e1949096（1-20）.
[8] Laila AG，Mar AC，Javier PG. Systematic Review：The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease [J]. Microorganisms，2021，9（997）：1-43.
[9] Mohammad T，Gregory CAA，Andrew RJM，et al. Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels [J]. Gut Pathog，2020，12（1）：1-8.
[10] Huang LJ，Mao XT，Li YY，et al. Multiomics analyses reveal a critical role of selenium in controlling T cell differentiation in Crohn’s disease [J]. Immunity，2021，54（8）：1728- 1744.
[11] Huang J，Yang ZY，Li YY，et al. Lactobacillus paracasei R3 protects against dextran sulfate sodium （DSS）-induced colitis in mice via regulating Th17/Treg cell balance [J]. J Transl Med，2021，19（356）：1-13.
[12] Clough JN，Omer OS，Tasker S，et al. Regulatory T-cell therapy in Crohn’s disease：challenges and advances [J]. Gut，2020，69（5）：942-952.
[13] Colombo F，Frontali A，BaldC，et al. Repeated surgery for recurrent Crohn’s disease：does the outcome keep worsening operation after operation? A comparative study of 1224 consecutive procedures [J]. Updates Surg，2022，74（1）：73-80.
[14] Tang WY，Liu JH，Peng CJ，et al. Functional Characteristics and Application of Mesenchymal Stem Cells in Systemic Lupus Erythematosus [J]. Arch Immunol Ther Exp （Warsz），2021，69（1）：7-17.
[15] Fang L，Hui C，Tao C，et al. Immunotherapeutic effects of allogeneic mesenchymal stem cells on systemic lupus erythematosus [J]. Lupus，2020，29（8）：872-883.
[16] Yu Q，Wang H，Zhang L，et al. Advances in the treatment of graft-versus-host disease with immunomodulatory cells [J]. Int Immunopharmacol，2021，92：1-10.
[17] Sun YY ，Liu J，Xu ZR，et al. Matrix stiffness regulates myocardial differentiation of human umbilical cord mesenchymal stem cells [J]. Aging （Albany NY），2020，13（2）：2231- 2250.
[18] Barati S，Tahmasebi F，Faghihi F. Effects of mesenchymal stem cells transplantation on multiple sclerosis patients [J]. Neuropeptides，2020，84（102095）：1-9.
[19] Panayiota P，Ibrahim K，Netta L，et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis [J]. Brain，2021，143（12）：3574-3588.
[20] Fatemeh RK，Shahab S，Seyed MM. Mesenchymal stem cells alter the frequency and cytokine profile of natural killer cells in abortion-prone mice [J]. J Cell Physiol，2022， 235（10）：7214-7223.
[21] Zhao YL，Su GH，Wang Q，et al. The CD200/CD200R mechanism in mesenchymal stem cells’ regulation of dendritic cells [J]. Am J Transl Res，2021，13（8）：9607-9613.
[22] Zhang ZY，Tian HZ，Yang C，et al. Mesenchymal Stem Cells Promote the Resolution of Cardiac Inflammation After Ischemia Reperfusion Via Enhancing Efferocytosis of Neutrophils [J]. J Am Heart Assoc，2020，9（5）：1-13.
[23] Zhao L，Tang Y，Lei N，et al. Clinical features and monocyte/macrophage subsets characterization in granulomatous vs non-granulomatous Crohn’s disease [J]. Scand J Gastroenterol，2020，55（4）：442-448.
[24] Zhao F，Zheng T，Gong W，et al. Extracellular vesicles package dsDNA to aggravate Crohn’s disease by activating the STING pathway [J]. Cell Death Dis，2021，12（9）：815- 820.
[25] Neda H，Hajar AK，Saeed NMK，et al. Adipose-derived mesenchymal stem cell-secreted exosome alleviates dextran sulfate sodium-induced acute colitis by Treg cell induction and inflammatory cytokine reduction [J]. J Cell Physiol，2021，236（8）：5906-5920.
[26] 李智伟，邢立行，张中洲，等.MSCs联合EPCs在组织工程血管化中的作用研究[J].农垦医学，2018，40（3）：193- 197.
[27] Santoro M，Awosika TO，Snodderly KL，et al. Endothelial/ Mesenchymal Stem Cell Crosstalk Within Bioprinted Cocultures [J]. Tissue Eng Part A，2020，26（5-6）：339- 349.
[28] Julián P，Damián GO，Gert VA，et al. Expanded allogeneic adipose-derived mesenchymal stem cells（Cx601）for complex perianal fistulas in Crohn’s disease：a phase 3 randomised，double-blind controlled trial [J]. Lancet，2016， 388（10051）：1281-1290.
[29] Panés J，García-Olmo D，Van AG，et al. Long-Term Results of Adipose-Derived Stem Cell Therapy for the Treatment of Crohn’s Fistula [J]. Stem Cells Transl Med，2015，4（5）：532-537.
[30] Wainstein C，Quera R，Fluxa D，et al. Stem cell therapy in refractory perineal Crohn’s disease：long-term follow-up [J]. Colorectal Dis，2018，20（3）：68-75.
[31] Raquel SB，Mariano GA，Hector G，et al. First-in-Human Case Study：Pregnancy in Women With Crohn’s Perianal Fistula Treated With Adipose-Derived Stem Cells：A Safety Study [J]. Stem Cells Transl Med，2015，4（6）：598-602.
[32] 李猛，刘艳，张雨婷，等.张苏闽治疗克罗恩病肛瘘临证经验[J].东中医药大学学报，2019，43（3）：279-283.
[33] Ciccocioppo R，Gallia A，Sgarella A. Long-term follow-up of Crohn disease fistulas after local injections of bone marrow-derived mesenchymal stem cells [J]. Mayo Clin Proc，2015，90（6）：747-755.
[34] 冯波，黎啸峰，彭海宁，等.人脐带间充质干细胞的安全性评价[J].激光生物学报，2022，31（1）：43-49.
[35] 吴姚钰，沈熙，宋伟，等.人脐带间充质干细胞生物急性毒性评测[J].南通大学学报，2021，41（4）：324-327.
[36] Gang W，Wu HL，Liu UP，et al. Pre-clinical study of human umbilical cord mesenchymal stem cell transplantation for the treatment of traumatic brain injury：safety evaluation from immunogenic and oncogenic perspectives [J]. Neural Regen Res，2022，17（2）：354-361.